Recombinant adenoviruses and uses thereof
AssigneeBeth Israel Deaconess Medical Center, Inc.
InventorsDan H. Barouch, Peter Abbink, Mark Justin Iampietro, Menzo J. E. Havenga
Life of this patent
Estimating the term…
Abstract
Featured are recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are simian (rhesus) adenoviruses having a low seroprevalence and high immunogenicity (when expressing, e.g., an antigenic polypeptide) relative to other adenoviruses and vectors thereof. Also featured are methods for producing the adenoviruses and methods of treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
Claims20
A recombinant adenovirus comprising a nucleotide sequence encoding a hexon protein, wherein the nucleotide sequence encoding the hexon protein has at least 93% sequence identity over the entire sequence of any one of SEQ ID NOs:
- 55, 58, 59, 61, 62, 64, 65, and 67, and wherein the recombinant adenovirus further comprises a deletion in or of the E1, E2, and/or E3 region.
A method of producing a recombinant adenovirus comprising:
- (i) transfecting a cell with an isolated polynucleotide or complement thereof comprising a nucleotide sequence encoding a hexon protein;
- (ii) culturing the cell in a suitable medium to allow replication of the polynucleotide in said cell;
- and
- (iii) harvesting recombinant adenovirus from the cell and/or from the medium, wherein the nucleotide sequence encoding the hexon protein has at least 93% sequence identity over the entire sequence of any one of SEQ ID NOs:
- 55, 58, 59, 61, 62, 64, 65, and 67.
Dependencies are inferred from the claim text.